Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $116,814 - $161,076
-600 Reduced 26.09%
1,700 $454,000
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $168,786 - $200,718
-900 Reduced 28.13%
2,300 $469,000
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $310,032 - $390,624
1,600 Added 100.0%
3,200 $674,000
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $134,352 - $172,662
600 Added 60.0%
1,600 $384,000
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $1.4 Million - $2.24 Million
-5,400 Reduced 84.38%
1,000 $294,000
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $1.31 Million - $1.54 Million
5,400 Added 540.0%
6,400 $1.79 Million
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $189,008 - $284,504
800 Added 400.0%
1,000 $245,000
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $3.02 Million - $3.49 Million
-11,400 Reduced 98.28%
200 $57,000
Q1 2020

May 15, 2020

BUY
$268.85 - $341.04 $1.29 Million - $1.64 Million
4,800 Added 70.59%
11,600 $3.67 Million
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $88,024 - $121,628
400 Added 6.25%
6,800 $2.02 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $241,219 - $265,892
-1,100 Reduced 14.67%
6,400 $1.5 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $1.63 Million - $2.54 Million
7,500 New
7,500 $1.77 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.